Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527554 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL18650671 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL17254874 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL20050054 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL4275422 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL18654187 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL25142231 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL18650646 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL4275427 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 | |
| SCHEMBL18650637 | 1.00 | GAA (0.58) | GAACDK1CCNB1ACHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-8173606-B2 | Sulfated oligosaccharide derivatives | PROGEN PHARMACEUTICALS LIMITED (AU) | 2012-05-08 | — | — | US | disclosed |
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LIMITED (AU) | 2011-06-02 | — | — | US | disclosed |
| US-7875592-B2 | inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease | PROGEN PHARMACEUTICALS LIMITED (AU) | 2011-01-25 | — | — | US | disclosed |
| US-20070185037-A1 | Sulfated oligosaccharide derivatives | PROGEN INDUSTRIES LIMITED (AU) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185037-A1 | Sulfated oligosaccharide derivatives | HPSE, APOB, LIPG | GAA 216/4885CDK1 3761/4885CCNB1 3703/4885 |
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | HPSE, APOB, LIPG | GAA 216/4885CDK1 3761/4885CCNB1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.